Capital Raising – Placement and Share Purchase Plan
8 August 2018 ASX ANNOUNCEMENT Capital Raising – Placement and Share Purchase Plan 1. Placement Medical Developments International (ASX: MVP) (Company) is pleased to advise that it has today successfully secured a placement of 4,250,000 ordinary shares in the Company to a number of sophisticated and wholesale investors at a price of $4.00 per share, […]
Read moreFY18 Results Update
For the full ASX Announcement “FY18 Results Update” please click on the following link:ASX Announcement – FY18 Results Update_060818
Read moreUSA Update
25 July 2018 ASX ANNOUNCEMENT USA Update Medical Developments International (ASX: MVP) today advised that it met with the Food and Drug Administration (?FDA?) for the United States of America overnight. The FDA has advised that the clinical program for Penthrox to be approved for sale in the USA is to be put on hold […]
Read morePenthrox approved in Italy, The Czech Republic and Spain
16 July 2018 ASX Announcement Penthrox approved in Italy, The Czech Republic and Spain. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Italy,?the Czech Republic and Spain. MVP CEO, Mr. John Sharman said, ?We are delighted to have received the approval for these countries and […]
Read morePenthrox approved in Portugal and Switzerland
25 June 2018 ASX Announcement Penthrox approved in Portugal and Switzerland. Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Switzerland and Portugal. MVP CEO, Mr. John Sharman said, ?The roll out of Penthrox across Europe continues. We are delighted to have received the approval from […]
Read moreMVP signs exclusive Distribution Deal for Iran
29 May 2018 ASX Announcement MVP signs exclusive Distribution Deal for Iran. Penthrox approved in Romania, Bulgaria, Slovenia & Cyprus. Medical Developments International Limited (ASX: MVP) is delighted to announce that it has concluded an exclusive Distribution Deal with Nikkan Pharma, part of the Darman Ara group of companies.? Darman Ara is one of Iran?s […]
Read moreTrading Update
14 May 2018 ASX Announcement Trading Update Medical Developments International Limited (ASX: MVP) CEO, Mr. John Sharman, warned today that despite the fact that during FY18 Penthrox has been approved for sale in 15 additional countries including Canada, Germany, Mexico, Sweden and numerous other European countries, the upside from this global expansion will not be […]
Read morePenthrox approved in Finland
24 April 2018 ASX Announcement Penthrox approved in Finland Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Finland. For the full release, please refer to the following link:?Penthrox approved in Finland
Read morePenthrox is approved in Canada
10 April 2018 ASX Announcement Penthrox is approved in Canada Medical Developments International Limited (ASX:MVP), announce today that PENTHROX?, has been granted Market Authorisation in Canada. The Marketing Authorisation issued by Health Canada allows PENTHROX? to be used for the short-term relief of moderate to severe acute pain, associated with trauma or interventional medical procedures, […]
Read morePenthrox approved in Germany
5 April 2018 ASX Announcement Penthrox approved in Germany Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Germany. MVP CEO, Mr. John Sharman said, ?We are excited that the Marketing Authorisation for Germany has been received.? Germany is one of the most important markets for […]
Read more